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Highlights: 
1. First report of MG prevalence and antimicrobial resistance in Wales. 
2. Second reported use of the SpeeDx prototype M. genitalium parC mutation assay. 
3. M. genitalium bacterial load was not related to symptomatic patient presentation. 
4. M. genitalium bacterial load between urine and swab samples are equivalent.  
5. Gender and age bias identified in M. genitalium prevalence. 
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ABSTRACT:  
Objectives: Mycoplasma genitalium (MG) is a common cause of sexually transmitted infection, 
however no prevalence data is available for Wales. MG was detected by qPCR (quantitative) as well 
as two separate SpeeDx commercial assays, and related to clinical symptoms, age, gender and 
sample type. 
Methods: Cervical swabs, urethral swabs and/or urine were collected from 1000 patients at walk-in 
sexual health clinics at 3 Welsh health centres from October 2017-October 2018. Extracted DNA was 
investigated to determine concordance between an in-house quantitative PCR, SpeeDx 
ResistancePlus® MG and the SpeeDx MG+parC (beta 2) assays; mutations in parC were substantiated 
by Sanger sequencing. 
Results: MG was detected in 17/600 female patients (2.7%) and 13/400 (3.5%) male patients, with a 
100% concordance between in-house qPCR and both SpeeDx assays.  Macrolide resistance was low 
(relative to other studies), but more common in males (4/13; 30.8%) than females (2/17; 11.8%) and 
the only fluoroquinolone resistant sample (3.4% overall) was also macrolide resistant and detected 
from an MSM. Vaginosis was clinically apparent in 12/17 MG-positive females (2 with additional 
cervicitis, 1 with additional pelvic inflammatory disease), while 7 MG-positive males were 
asymptomatic.  MG bacterial load did not correlate to clinical symptoms and females (4,559 ± 
1,646/ml) had significantly lower MG load than males (84,714 ± 41,813/ml; p=0.0429).   
Conclusions: MG prevalence and antibiotic resistance in Welsh sexual health clinics is low. MG 
bacterial load did not correlate to clinical presentation, men have higher MG load/ml in urine than 
women, genders have different age bias for MG prevalence and urine and swabs are equivalent for 
detecting MG. 
  
Spiller et al. MG in Wales 
3 | P a g e  
 
1. INTRODUCTION. 
Mycoplasma genitalium (MG) is a 600-700 nm flask-shaped motile bacterium with a genome of 
approximately 580 kb that is transmitted by sexual contact [(1)].  It is generally accepted that MG 
infection causes urethritis in men [(1,2)] and is associated with increased risk of cervicitis, pelvic 
inflammatory disease, preterm birth, and infertility in women [(3)].  While the MG is gaining 
acceptance as a causative agent for these sexual health maladies, some authors postulate that only a 
minority of men infected with MG develop urethritis, while many remain asymptomatic [(2)]. The 
2015 UK guidelines on non-gonococcal urethritis recommend not testing asymptomatic men [(4)].   
Only two main population studies have provided general prevalence data for MG.  In the US, a 
school-based random sampling of 18-27 year olds found 1.1% in 1218 men and 0.8% in 1714 
women. While the Natsal-3 study examined a subset of 4507 urine samples from 15,162 randomly 
selected members of the UK public to find MG prevalence of 1.2% in men and 1.3% in women 
between the ages of 16-44 [(5)]. However, these studies were not designed to determine the ratio of 
symptomatic to asymptomatic individuals infected with MG. Bias in MG prevalence, investigating 
high versus low risk sexual activity groups was highlighted in a French study finding 4% MG in 
samples from presumptive high-risk sexual behaviour patients (STI, abortion, family planning and 
penitentiary centers) compared to 1.7% MG prevalence in gynaecological, obstetric and 
reproduction patients [(6)]. Studies examining MG prevalence in sexual health based environments 
have found higher rates: 5.3% (male) and 7.2% (female) in Western Canada (N=2254) [(7)], 17.2% 
(male) and 16.1% (female) in the US (N=964) [(8)], 10.3% (male) and 3.8% (female) in Denmark 
(N=7361) [(9)]. A study examining MG samples submitted at Swedish youth Chlamydia trachomatis 
(CT) and gonococcal (GC) screening clinics reported 9.8% MG prevalence, however, as only samples 
from 15–25 year olds [(10)] were investigated; this may skew the prevalence as 15–24 year olds are 
also known to have the highest CT prevalence. An aspect of MG prevalence that requires further 
clarification. 
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Treatment failure of MG with Azithromycin and moxifloxacin is a well-established trend: A poignant 
study in 2015 identified hallmark mutations in the 23S rRNA and topoisomerase/gyrase genes in 
isolates from patients with treatment failure [(11)]. Current studies are almost completely 
dependent on molecular methods to determine “resistant” MG infections (as defined by the 
presence of these mutations) as MG is extremely fastidious [(1,12)].  Key studies have combined in 
vitro MIC values to MG genomic sequences to validate the underlying mechanisms for the more 
frequently reported mutations in 23S rRNA, gyrA and parC genes [(13,14)].  Resistance-mediating 
mutations vary geographically as wells due to patient sexual demographics/risk behaviour. 
Macrolide resistance-mediating mutation (MRM) and fluoroquinolone resistance-mediating 
mutation (FRM) prevalence in 358 urethral MG isolates from symptomatic men attending Chinese 
sexual health clinics were found in 88.9% and 89.5% of sequenced isolates, respectively [(15)].  At 
the other extreme no MRM and only 0.4% established FRM prevalence rates were reported for 266 
MG isolates from HIV and STI patients in South Africa [(16)].   
Here we report the first MG prevalence study in Wales, investigating 1000 participants attending 3 
walk-in sexual health clinics from October 2017 to September 2018.  Evidence of MG infection was 
correlated between an in-house qPCR assay and the commercial SpeeDx ResistancePlus® MG assay to 
determine the MG MRM prevalence. We also present the results from the prototype SpeeDx MG+parC 
(beta 2) assay relative to Sanger sequencing of the parC gene for all isolates.  We also correlate the MG 
bacterial load to clinical symptoms in the participants, MG bacterial loads between genders and 
sample type, as well as examine differing age biases for MG prevalence between men and women. 
2. MATERIALS AND METHODS. 
2.1  Participant samples.  First-void Urine and/or swabs (urethral, endocervical or high vaginal swabs) 
were collected from informed and consented participants from October 2017 to October 2018 
attending Welsh sexual health walk-in clinics held at Dewi Sant hospital (Pontypridd), Keir Hardie 
Health Park (Merthyr Tydfil), or Ysbyty Cwm Cynon (Mountain Ash).  Samples were obtained following 
informed consent, from a cross-section of all patients attending walk-in sexual health clinics, under 
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ethical approval (IRAS 230693) and results of analysis for MG were linked to patient notes under 
subsequent ethical approval (IRAS 253889).  Six hundred female participants were recruited 
(symptomatic female patients included 31 with pelvic inflammatory disease, 16 with cervicitis and 176 
with vaginitis) and four hundred male participants were recruited including 84 male patients with 
urethritis (69 of which were negative for both Chlamydia or gonococcus), 9 with balanitis (6 exclusive 
of urethritis) and 22 with epididymitis (21 exclusive of urethritis or balanitis) summarised in Table 1.  
All patients presenting with symptoms were additionally investigated for the presence of Chlamydia 
trachomatis (CT) or Neisseria gonorrhoea (GC) by standard NHS diagnostic procedure by submitting a 
urine or swab (as appropriate) sample using Roche diagnostics samples for cobas® CT/NG assay testing 
utilising a cobas® 4800 (Roche Molecular Systems, Pleasanton, CA). 
Table 1. Bacterial infections and clinical diagnoses of 1000 Sexual health walk-in participants. 
FEMALES Total Vaginitis PID Cervicitis None of these 
Total in 600 600 203 31 16 395 
CT 30 24 1 1 6 
GC 8 6 0 1 2 
CT+GC 2 2 0 0 0 
Syphilis 1 0 0 0 1 
MG 17 12 1 2 5 
MG+CT 2 2 0 0 0 
MG+CT+GC 1 1 0 0 0 
MALES Total Urethritis Balanitis Epididymitis None of these 
Total in 400 400 84 9 22 285 
CT 20 0 0 1 19 
GC 6 4 0 0 2 
Syphilis 4 0 0 0 4 
MG 14 7 0 0 7 
MG + CT or MG 0 0 0 0 0 
Legend: CT = Chlamydia trachomatis, GC= Neisseria gonorrhoea (gonococcus), MG= M. genitalium. 
2.2  Clinical evaluation of participants: Patients with a female reproductive system were clinically 
assessed by a sexual health specialist and symptoms, signs on examination, and specific 
investigations were used to make a diagnosis in accordance with guidelines set out by the British 
Association of Sexual Health and HIV (BASHH) and Royal College of Obstetrics and Gynaecology,  as 
listed in Supplementary table 1; e.g. bacterial vaginosis, non-specific vaginitis, cervicitis or pelvic 
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inflammatory disease (PID). Similarly, patients with a male reproductive system were diagnosed with 
urethritis, balanitis or epididymitis using BASHH guidelines as listed in Supplementary table 1. 
Participants recruited in walk-in clinic without symptoms relevant to MG infection included those 
with complex contraceptive needs, genital wart treatments, herpes infection and genital 
dermatoses. All findings, diagnoses and treatments were recorded in the participant’s notes along 
with clinical history and demographic parameters (e.g. age, gender identity, the number of sexual 
contacts, whether patients engaged in oral, vaginal or anal sex etc.) and notes were retrospectively 
linked to research laboratory findings at the conclusion of patient recruitment. 
2.3  Sample processing. Urine samples were processed as follows:  2 ml of urine were centrifuged at 
15,000xg for 20 min, supernatant removed and pellet frozen at -86oC until extraction of DNA using 
the Qiagen QiaCube automated system.  Swab samples were processed as follows: Copan Rayon 
swab samples were either taken by the clinician (endocervical) or self-taken by the participant (high 
vaginal), material was re-suspended in 10 ml sterile saline (CPM S.A.S., Rome, Italy) within 20 min 
and 2 ml centrifuged and processed for DNA extraction as above.  DNA extracts were stored at -86oC 
until batch analysed by quantitative PCR. 
2.4  Molecular analysis. Analysis of the previously published MgPa380 probe [(17)] determined that its 
calculated Tm=51.5oC and the accompanying MgPa355F primer has a calculated Tm=59.1oC (but also is 
predicted to have a hairpin with a Tm=48.9oC) and is found to have a one SNP mismatch compared to 
the whole genome sequence for strain M6282 (Genbank accession: CP003771).  Therefore new 
primers and probes conserved between all published MG sequences with Tm≥60oC were designed: 
Primers mgpB_BnB_FP GAAGGTATGATAACAACGGTAGAGCTT and mgpB_BnB_RP  
CCATTTAAACCCCTTTGCACCGT with Taqman hydrolysis probe mgpB_BnB_HP [CY5]-
ACTTAGCAAAAATGGAAAACCCCTC-[BHQ650]. Five microliters of extract were added to 15µL 
SsoAdvanced Universal Probes Supermix (Bio-Rad Laboratories) and 1 cycle of 5 min at 95oC, then 45 
cycles of 15 seconds at 95oC and 15 seconds at 60oC were analysed by integral CFX Maestro™ Software 
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in the CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad Laboratories). Genome copies were 
calculated against a 6-log dilution curve (106-101 copy) of the G37 strain (accession NC_000908.2) P1 
gene (nucleotides 350-481), synthesised by GenScript Biotech (Netherlands). Five microliters were 
additionally analysed using the SpeeDx ResistancePlus MG assay and MG positive samples were 
additionally analysed by the SpeeDx MG+parC (beta 2) assay for fluoroquinolone parC mutations 
A247C (S83R), G248T (S83I), G248A (S83N) or G259T (D87N), G259A (D87N) or G259C (D87H).  Results 
for SpeeDx assays were analysed according to the manufacturer’s instructions and parC sequence was 
confirmed by Sanger sequencing (Source Biosciences, Cambridge UK) amplicons generated using parC-
MG_RP533 ATCCAGCAGCTATCCCACTC and parC-G37_FP with GCTTAAAACCCACCACTCCC or parC-
M6282-FP GCTTAAAACCCACCACTTCCT. 
2.5  Statistical analysis.  All statistical analyses were performed using GraphPad Prism version 7 
(GraphPad Software). Descriptive statistics (i.e. bacterial load per gender, etc.) were presented as 
average ± standard deviation and prevalence ranges included 95% confidence interval (CI95%). MG 
bacterial loads were log10 transformed to fit a normal distribution and correlations were calculated 
using Pearson correlation assuming a Gaussian distribution and results were presented as R2 values, 
which were highly significant (P<0.0001).  Significance was only attributed to comparisons where P 
value <0.05.  
3. RESULTS. 
3.1 Prevalence of M. genitalium in Wales. Thirty individual participants from the recruited 1000 
sexual health clinic walk-in patients were found to be positive for M. genitalium (MG).  All MG-
positive samples were detected by the SpeeDx ResistancePlus MG assay, the SpeeDx MG+parC (beta 
2) assay and the in-house BnB_MgPa Taqman hydrolysis probe qPCR assay. MG-positive samples 
were found in 17/600 female patients (2.7%; CI95%=1.5-4.0%) and 13/400 (3.5%; CI95%=1.7-5.2%) male 
patients.  Eleven of the male participants were heterosexual and 2 were MSM (men who have sex 
with men). Only one male participant was detected on two separate occasions in samples taken 1 
month apart (i.e. 14 separate male samples positive for MG).  Quantitative PCR measurement of MG 
Spiller et al. MG in Wales 
8 | P a g e  
 
Bacterial load measured genomic copy number to be 4,559 ± 1,646 per ml sample provided for all 
female participants and 84,714 ± 41,813 per ml for male participants (Figure 1A; p=0.0429; t-test).  
Of the 17 MG-positive female participants, 12 had clinical evidence of vaginitis, 2 had cervicitis and 1 
was diagnosed with pelvic inflammatory disease, while 5 were asymptomatic (29.4%). Two of the 
MG-infected female participants with vaginitis were found to be co-infected with CT and an 
additional participant with vaginitis was co-infected with both CT and GC (Table 1); however, CT and 
GC were absent from the 3 cases of PID and cervicitis. Of the 14 MG-positive male samples, none 
were co-infected with CT or GC and 7 had clinical evidence of non-specific (or non-gonococcal) 
urethritis (50%), while 7 were asymptomatic (as the participant with two positive samples was 
symptomatic on his first visit, but asymptomatic on his follow-up visit). 
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Figure 1. M. genitalium bacterial load, as determined by Taqman hydrolysis probe qPCR 
measurement against a 6-point standard curve. A. Difference in MG copies/ml between male and 
females (p=0.043). B. Results segregated between asymptomatic female patients compared to those 
with vaginitis, cervicitis and pelvic inflammatory disease diagnoses and asymptomatic male patients 
compared to those with urethritis diagnoses. 
 
3.2 Symptomatic presentation is not related MG bacterial load. No relationship could be found 
between MG load and symptomatic presentation (co-infected participants excluded) (Figure 1B): 
asymptomatic females had 1,770 ± 992 (range 130-5,500) MG Geq/ml compared to 5,721 ± 2,240 
(range 140-26,750) MG Geq/ml (p=0.288) in participants with vaginosis and asymptomatic males had 
32,840 ± 21,649 (range 80-140,000) MG Geq/ml compared to 136,587 ± 78,807 (range 1,550-
600,000) MG Geq/ml (p=0.228) in those with urethritis.  Of the 17 MG-positive female patients, 6 
samples were submitted as swabs only, 6 provided a urine sample only and 5 provided both sample 
types that were processed individually.  One of these was MG-positive for swab sample only (236 
Geq/ml) and another was MG-positive for urine sample only (3880 Geq/ml), while the remaining 
were MG-positive for both sample types (Supplementary figure 1).  No consistent pattern for higher 
MG levels between sample type were apparent in these three dual MG-positive female samples.  
While the average MG copy number appeared higher for all female urine samples (5,525 ± 2,547 
Geq/ml) relative to all female swab samples (2,636 ± 1,240 Geq/ml), this comparison failed to 
achieve statistical significance for this small sample size.   
3.3 Gender and age bias in MG prevalence. The average age was 28.8 years (CI95%=28.0-29.6) for 
female participants and 30.9 years (CI95%=29.8-32.0) of age for males (range 16-68 for both genders). 
More participants were present for 16-24 years (36.0% females; 41.5% males) and 25-34 years 
(36.5% females; 34.8% males) compared to older age groups of 35-44 (14.4% females; 15.3% males) 
and over 45 (13.1% females; 8.3% males).  While MG infection did not differ by gender, a general 
trend in age demographics was observed: a steady decline in percent MG infection was observed 
from the 16-24 age group in female participants, while MG infection rates increased to peak in the 
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35-44 age group in men, before dropping sharply off (Figure 2). While the numbers of infected 
patients are small, it is notable that this was the exact trend observed in a French study of 2652 
samples collected from 2014-2015 [(6)] (Figure 2).   
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Figure 2. M. genitalium prevalence as a percentage of patients investigated stratified by age group. 
Male patients identified as grey squares and female patients identified as grey circles.  All patients 
determined as positive by SpeeDx ResistancePlus MG, SpeeDx MG+parC (beta 2) and our in house 
qPCR recognising the major surface antigen MgPa. Data for French patients (2014-2015) reported 
previously [(6)] shown in open symbols with dotted lines for comparison. 
 
3.4 Concordance between bacterial load and commercial assay Cq value. There was a complete 
concordance for MG detection between in-house qPCR and the results for the SpeeDx 
ResistancePlus MG and SpeeDx MG+parC (beta) assays (including the MG-negative female swab and 
urine sample from matched samples above).  The Cq values for MgPa detection in each assay nearly 
identical between the ResistancePlus MG and SpeeDx MG+parC (beta 2) assays; furthermore, these 
Cq values correlated very closely to a log10 transformation of the Geq values determined by our in-
house assay for the same samples (Figure 3; Pearson R2=0.933).  This indicates that the cycle number 
at which the SpeeDx probe for MgPa crosses the threshold can give a rough indication of how high 
the MG load is: 10 MG Geq per well was consistently about 27 cycles, 100 Geq per well about 23.5 
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cycles, 1000 Geq per well about 21 cycles, and any samples ≤17 cycles were consistently ≥10,000 
Geq per well.    
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Figure 3. Correlation between SpeeDx MgPa probe Cq (calculated cycle number crossing positive 
threshold) and genomic copy number (Geq) per well as determined by our in-house Taqman 
hydrolysis probe (determined against a 6-point standard curve). 
3.5 Confirmation of commercial ParC mutation results by Sanger sequencing. The SpeeDx 
ResistancePlus MG assay is currently a commonly used and accepted in vitro diagnostic utilised for 
identifying macrolide resistance-mediating mutations (MRM) [(18)].  In our cohort 4/13 male 
patients had MRM (30.8%) and 2/17 female patients had MRM (11.8%) giving an overall MRM 
prevalence of 20%.  We also tested the prototype SpeeDx MG+parC (beta 2) molecular test for 
determining the presence of the most common ParC mutations associated with fluoroquinolone 
resistance (S83I, S83R, S83N, D87N, D87Y, and D87H).  Screening the 30 MG-positive samples in our 
1000 patient cohort we only identified one patient (3.3%) with an S83I/S83R and Sanger sequencing 
of this isolate confirmed the presence of an A248T (S83I) mutation, in an isolate that concurrently 
contained an MRM mutation (16.6% of 6 MRM-MG positive samples).   
3.6 Anecdotal observations from repeat samples in patient subset. Post-study analysis (MG-testing 
was blinded and clinical MG testing was not available in the clinics at the time of study) allowed us to 
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follow five patients (Supplementary figure 2): A symptomatic male patient with MG load of 23,180 
Geq/ml sample, was treated with doxycycline for 7 days and was asymptomatic on follow-up 28 days 
later despite still having an MG load of 87,360 Geq/ml (patient had no other detectable organisms in 
their samples, MG was macrolide sensitive).  A second symptomatic male patient with an MG load of 
71,220 Geq/ml sample, was treated with 2g azithromycin over 4 days and was asymptomatic with no 
detectable MG 2 weeks later (MG was macrolide sensitive). A symptomatic female patient with an 
MG load of 10,410 Geq/ml (urine) and 670 Geq/ml (swab) was treated with doxycycline and 
metronidazole for 7 days and returned asymptomatic with no detectable MG 3 weeks later 
(macrolide resistant MG). A final participant being treated for herpesvirus that did not have 
urethritis, had an MG load of 390 Geq/ml and self-resolved without use of antibiotics 28 days later.  
A single participant (one of two MG-positive MSM participants) in this study was asymptomatic with 
an MG load of 980 Geq/ml returned and was still asymptomatic 9 months later (participating in a 
subsequent study) with an MG load of 56 Geq/ml; worryingly both samples contained combined 
macrolide and fluoroquinolone resistance markers. 
4. DISCUSSION. 
To date, several small-scale prevalence studies have been reported and MG prevalence 
estimates vary widely. An unbiased population sampling in the UK (Natsal-3) from 2010-2012 
determined the MG rates to be 1.2% in men and 1.3% in women [(5)], while MG prevalence in 
sexually active young women (17-27 years old) in England between 2004-2008 was found to be 
3.3% [(19)].  A recent French study has shown that significant difference is to be expected 
between sampling of low-risk (1.7% MG) and high-risk (4.0% MG) sexual activity biased 
populations [(6)]. Here we present the first MG prevalence study for 1000 participants attending 
Welsh walk-in sexual health clinics: MG was detected in 2.8% of female participants (4.2% of the 
17-27 age group) and 3.3% of males. Differences observed in Welsh MG prevalence trends 
between the genders for various age groups also closely mirrored observations in French 
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patients [(6)] (Figure 3).  This same gender-biased MG trend can also be observed (albeit with 
lower prevalence) in the unbiased Natsal-3 UK data [(5)]. 
The rapid global emergence of antimicrobial resistance (with limited therapeutic options) has 
propelled development of MG detection with antimicrobial resistance (AMR) determination to a 
high international priority. The SpeeDx ResistancePlus MG assay was found to have a specificity of 
100%, sensitivity of 94.9% and an accuracy for determination of MRM of 92.4% for MG-positive 
samples from England [(18)]. We found specificity and sensitivity of 100% relative to our in-house 
qPCR, with a close correlation between the Cq values for the MgPa gene in SpeeDx assays to our 
calculated MG bacterial load (R2= 0.933). We also report the second use of SpeeDx MG+parC (beta 2) 
assay in the literature [(20)] (this is the first in the UK), and we found a complete concordance with 
parC Sanger sequencing of all isolates.  
Similar to recent reports from Australia and Canada [(7,21)], we found MG-MRM rates higher in 
males (30.8%) compared to females (11.8%).  However, our overall MRM rate (20%) was much lower 
than the 82.4% MRM recently reported for England [(22)], as well as those reported recently for 
China (88.9% [(15)]), Queensland Australia (75.9% [(17)]), New Zealand (77.4% [(23)]), Alberta 
Canada (66.2% [(7)]), and Germany (52.6% [(24)]).  Our 3.3% overall fluoroquinolone resistance 
mutation (FRM) rate was similar 4.9% to England (4.9% [(22)]). FRM rates also vary geographically: 
0.4% in South Africa [(16)], 4.7% in France [(25)], 10.5% in Germany [(24)], 12.2% in Western Canada 
[(7)], 23.3% in New Zealand [(23)] and 89.5% in China [(26)].  MG AMR rates have previously been 
reported for MSM populations [(11,21,27)], and it is notable that our only dual resistant MG isolate 
was found in a sample from an MSM participant.  However, we found the overall MG rates roughly 
the same between MSM (2/79; 2.5%) and heterosexual men (12/321; 3.4%), as expected based on 
other reports [(27)]. 
Opinion varies widely regarding asymptomatic carriage of MG, often obscured by the use of self-
reported symptoms in some reports compared to classification by sexual health clinicians in others.  
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A recent review suggested that infection in men is usually asymptomatic and it is likely that most 
men resolve infection without developing disease [(2)] and contemporary study groups have 
highlighted the need for unlinked anonymous monitoring of MG in sexual health populations [(28)]. 
Retrospective linking of MG results to physician-determined clinical status of participants in our 
study identified that 50% MG-positive male participants had urethritis (no co-infections were 
observed), while 71% of female participants had vaginitis (64% with CT and GC co-infections 
excluded).  This compares to 10% asymptomatic MG-infection in New Zealand [(23)], 70.9% 
asymptomatic MG-infections in France [(6)], 58-60% asymptomatic MG-infections in Western 
Canada [(7)] and 17% asymptomatic females versus 55% asymptomatic males enrolled in clinics 
across the USA [(8)].  However, proctitis does not appear to be caused by MG infection [(29)] despite 
MG rates being almost 3 times more frequent relative to urine samples for some populations. Most 
importantly, we found that there was no significant correlation between clinical presentation 
(urethritis or vaginitis compared to asymptomatic patients) and MG bacterial load in our study 
(Figure 1), which is in contrast to a previous report [(30)].   We did identify one asymptomatic male 
participant with very low MG bacterial load that resolved without any therapy as well as a second 
male participant that had very low MG bacterial loads in samples 9 months apart.  MG bacterial load 
was significantly higher in men than in women (Figure 1A), but this was not due to sample type bias 
since swabs and urine samples were comparable in matched samples from women (Supplementary 
Figure 1).  Gratrix et al. [(7)] also found a 98.1% concordance in MG detection between urine and 
swabs taken from the same patient and also found both swab and urine samples from women 
occasionally missed MG detection in matched samples. Therefore, unlike CT screening MG detection 
is not superior in swab samples for women. 
In conclusion, our study has the same limitations common to all broad population screening studies 
where participants are a combination of symptomatic patients seeking treatment, asymptomatic 
individuals requiring complicated contraception, worried well, contact tracing, and those requiring 
health monitoring due to long-term therapy, with the bias that they represent a sexually active 
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cohort.  We observed an MG prevalence concordant to other international studies, with the same 
gender biased trends in age groups as other studies.  We found lower AMR rates in MG compared to 
those reported in England [(22)] and found that MG bacterial load is not correlated to symptomatic 
clinical presentation.  We found one asymptomatic participant with low MRM/FRM MG levels 
detected 9-months apart; longer term follow-up of  these patients is required to see if chronic MG 
carriage eventually manifests as symptomatic infection and the importance of asymptomatic 
individuals passing antimicrobial resistant strains to other sexual contacts. 
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Supplementary Table 1.  DIAGNOSTIC CRITERIA USED FOR SYMPTOMATIC PATIENTS IN 
ACCORDANCE WITH BASHH GUIDELINES 
DIAGNOSIS SYMPTOMS SIGNS INVESTIGATIONS 
URETHRITIS Urethral discharge, dysuria, 
penile irritation, urethral 
discomfort. 
Muco-purulent 
urethral discharge, 
balano-posthitis 
5 or more PMNL’s per high 
power microscopic field on 
urethra smear. 
Threads in 1st pass urine; +/-  
>1+ leucocyte esterase dipstick 
on FPU.* 
BACTERIAL 
VAGINOSIS 
Abnormal vaginal 
discharge. Absence of 
pruritus, soreness or 
irritation. 
Thin homogenous 
discharge pH>4.5 
with no macroscopic 
evidence of 
inflammation. No 
vaginal erythema or 
oedema. 
HVS microscopy and culture. 
No organisms detected on 
direct plating to fungal media. 
Chlamydia and Gonorrhoea 
NAAT negative.. 
NON-
SPECIFIC 
VAGINITIS 
Vulval pruritus, vulval 
soreness, abnormal vaginal 
discharge, vaginal 
discharge, superficial 
dyspareunia, external 
dysuria. No history of vulval 
dermatoses or allergy. 
Vaginal discharge, 
vulval erythema +/- 
oedema, erythema of 
vaginal walls. 
Absence of signs of 
dermatological 
conditions or allergy. 
HVS for microscopy and 
culture. No organisms on 
Candida testing (direct plating 
to fungal media), Gardnerella 
and TV. Chlamydia and 
Gonorrhoea NAAT, Syphilis 
serology. 
CERVICITIS Abnormal discharge, post-
coital bleeding +/- 
intermenstrual bleeding, 
dyspareunia. Absence of 
CIN or cervical neoplasia. 
Purulent endocervical 
exudate, contact 
bleeding of 
ectocervix in absence 
of ectropion, 
strawberry cervix.  
Microscopy and culture of 
endocervical swab. 
30 or more PMNL per high 
power field.  
No organisms detected on 
Candida testing (direct plating 
to fungal media), Gardnerella 
and TV. Chlamydia and 
Gonorrhoea NAAT. 
PID Abnormal vaginal 
discharge, deep 
dyspareunia, lower 
abdominal/pelvic pain, 
post-coital bleeding +/-
abnormal vaginal bleeding. 
Absence of co-existing 
gynaecological conditions 
 
Adnexal tenderness, 
cervical motion 
tenderness, pain on 
bimanual 
examination of 
uterus. 
5 or more pus cells on 
endocervical microscopy. No 
organisms detected on 
Candida testing (direct plating 
to fungal media), Gardnerella, 
TV, Chlamydia and Gonorrhoea 
NAAT, Syphilis serology. 
EPIDIDYMITIS Scrotal pain (unilateral), 
swelling +/- urethral 
discharge. 
 
 
 
 
Tenderness and 
swelling of 
epididymis, +/- 
urethral discharge, 
absence of 
spermatocoele 
/herniae /torsion 
/varicocoele. 
Urethral swab for microscopy 
and culture. 
Urine for CT/NG NAAT. 
Urine dipstick negative 
(eliminated UTI).  
*Not all male participants had leucocyte esterase dipstick on FPU.   
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Supplementary Figure 1.  M. genitalium bacterial load as determined by in house qPCR for matched 
urine and swab samples from 5 female patients.  MG was only detected in one patient in the swab 
sample and only detected in the urine sample of another patient.  Of the remaining 3 patients MG 
bacterial loads were similar for both samples. 
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Supplementary Figure 2.  M. genitalium bacterial load as determined by in house qPCR participants 
(Ptx) with between visits to clinic from participants (antibiotics received between visits are given in 
parentheses for Ptx 1, 2 and 3.  MG was detected in two participants that were asymptomatic, one 
of which self-resolved (Ptx 5), as results were not made available to the clinicians no treatment was 
required for these two individuals. Time between samples: Ptx1 = 4 weeks, Ptx2 =2 weeks, Ptx3= 3 
weeks, and Ptx5 = 4 weeks.  It is notable that the time between visits for Ptx 4 was 9 months and this 
isolate was the only dual macrolide and fluoroquinolone resistant isolate in the study. 
